Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

ZVRA

NASDAQ

Zevra Therapeutics (ZVRA)

10.47 USD +4.65% vs prior close Oct 20, 2026
Zevra Therapeutics, Inc. price graph
24 sessions
13 9 17 Sep 20 Oct

The line runs 12 USD on 17 September through 10.47 USD on 20 October, on a scale from 9 to 13. Days the market did not trade hold the previous close, flat.

Market cap
622.7M USD
P/E (TTM)
8.7
Revenue, year to Dec 2025
106.5M USD
EPS, diluted, year to Dec 2025
1.35 USD
52-week range
8.11 USD – 14.74 USD
Avg volume
97.3K

as of Oct 20, 2026

Have Zevra Therapeutics (ZVRA) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Zevra Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 12 Oct 2026

0buys
1sells
$225Knet sold
1other filings
Have Zevra Therapeutics (ZVRA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
12 Oct 2026McFarlane Neil F.President and CEOSell20,000225K USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Zevra Therapeutics (ZVRA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Oct 2026McFarlane Neil F.President and CEOOption exercise50,000

Which funds hold Zevra Therapeutics (ZVRA)?

5 of the 45 institutional funds we track reported a Zevra Therapeutics position for the quarter ended 30 Sep 2026 — a combined 26.5M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Zevra Therapeutics (ZVRA)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Held (±25%)1,267,68613.9M USD−3.0%
Citadel AdvisorsAdded448,9344.9M USD+3,589.8%
Millennium ManagementAdded408,3394.5M USD+351.4%
Two Sigma InvestmentsAdded151,7541.7M USD+132.7%
AQR Capital ManagementTrimmed136,0991.5M USD−28.7%
Marshall WaceExited
Tudor Investment CorpExited

What has been filed or recorded for Zevra Therapeutics (ZVRA)?

The filings we hold for Zevra Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 22 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Zevra Therapeutics (ZVRA)?
And
22 Oct 2026Fails to deliverShares failed to deliver153 shares2K USD notional · <0.001% of shares out
13 Oct 2026Fails to deliverShares failed to deliver103 shares1K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.26 USD
30 Sep 2026FinancialsTotal assets313.6M USDat period end
30 Sep 2026FinancialsTotal equity238.9M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 0.14 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.60 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 1.35 USD
31 Dec 2025FinancialsRevenue106.5M USDfiscal year
31 Dec 2025FinancialsNet income83.2M USDfiscal year
31 Dec 2025FinancialsDiluted EPS1.35 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.01 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 1.21 USD
31 Mar 2025Quarterly earningsQ1 2026 reportedEPS −0.06 USD
31 Dec 2024Annual reportFY 2025 reportedEPS −2.28 USD

What do people ask about Zevra Therapeutics (ZVRA)?

From live data
What did Zevra Therapeutics shares close at?10.47

Zevra Therapeutics closed at 10.47 USD on 20 Oct 2026, up 4.65% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Zevra Therapeutics’ market cap?622.7M

Zevra Therapeutics is worth 622.7M USD by market value as of 20 Oct 2026, which is the share price times the shares on issue from its SEC filings.

What is Zevra Therapeutics’ P/E ratio?8.7

Zevra Therapeutics has a price-to-earnings ratio of 8.7, as of 20 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Zevra Therapeutics’ revenue?106.5M

Zevra Therapeutics reported revenue of 106.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Zevra Therapeutics insiders bought or sold shares recently?1 sale

In the 90 days to 22 Nov 2026, Zevra Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Zevra Therapeutics?5 of 45

5 of the 45 funds we track reported a Zevra Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Citadel Advisors and Millennium Management. See Funds

When did Zevra Therapeutics last report earnings?0.26

Zevra Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.26 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words